Kalfert D.,Klinika Otorinolaryngologie a Chirurgie Hlavy a Krku |
Ludvikova M.,Ustav Biologie |
Pesta M.,Ustav Biologie |
Topolcan O.,Laborator Imunochemicke Diagnostiky
Vnitrni Lekarstvi | Year: 2014
Vitamin D was lately introduced as the important anti-cancer agent with therapeutic potential to be used in prevention and therapy of malignant tumors. Head and neck squamous cell cancer (HNSCC) is the sixth most common cancer in the world. Prognosis of this cancer is in most patients poor. In attempts to improve therapy of this cancer, contemporary research is focused on extension of the etiological and pathobiological aspects of cancerogenesis of HNSCC. This fact provoked us to summarize present scientific knowledge about etiopathological, chemopreventive and therapeutic role of vitamin D in head and neck squamous cancer and outline the direction of further research in this interesting and from clinical point of view important field.
Fuchsova R.,Laborator Imunochemicke Diagnostiky |
Topolcan O.,Laborator Imunochemicke Diagnostiky |
Klecka J.,Urologicka Klinika |
Vrzalova J.,Laborator Imunochemicke Diagnostiky |
And 4 more authors.
Klinicka Biochemie a Metabolismus | Year: 2013
Objective: Monitoring changes in the levels of biomarkers PSA, %fPSA, [-2]proPSA and calculation of PHI in the diagnostic algorithm of early prostate cancer. Design: Pilot study Material and Methods: The Immunoanalytical Laboratory of University Hospital in Pilsen examined sera of 76 patients from the Urology department of the University Hospital with suspected prostate cancer who have undergone TRUS biopsy. We assessed the levels of PSA and, if the interval of PSA was between 0-30 μg/l, we also assessed the levels of freePSA, [-2]proPSA and we calculated %fPSA and Prostate Health Index (PHI). The monitored biomarkers were measured using the chemiluminescent DxI 800 instrument (Beckman Coulter, USA). All statistical analyses were calculated using the SAS version 9.2 software. Results: We found statistically significant increased levels of [-2]proPSA and PHI in patients diagnosed with prostate cancer by prostate biopsy vs. patients with benign prostate hypertrophy ([-2]proPSA median 14 vs. 27 ng/l, PHI median 35 vs. 77). On the contrary, we did not find any significant difference in tPSA and %freePSA (median tPSA 7.1 vs. 7.7 μg/l and %freePSA 16 vs.11.4%). Conclusion: The assessment of [-2]proPSA and the calculation of PHI appear to be of great benefit for a more accurate differential diagnosis of benign hyperplasia. © Ceská lékarská spolecnost Jana Evangelisty Purkyne, Praha 2013.